A majority (64% of respondents) feel confident that the first two doses of the vaccine are enough which is why they are reluctant to get the precautionary dose. However, the effectiveness of vaccination can go weak with time.
Pfizer CEO Albert Bourla also said that two doses of the company’s vaccine may not provide strong protection against infection from the COVID omicron variant, and to be able to prevent hospitalization.